SM-102
Related material for LNP research.
View product →Select a pack size below, or contact our team for custom quantities and availability.
The US$450 add-on covers all three supporting components. LQ089 is quoted separately. Components are supplied separately; RNA, buffer and formulation service are not included.
LQ089 is a tertiary-amine ionizable lipid reported in patent CN118506877A for mRNA lipid-nanoparticle research. In the cited luciferase-mRNA formulation, LQ089 LNPs showed higher whole-body reporter-expression exposure than the MC3 comparator after intravenous administration in mice. These preclinical results apply to the reported complete formulation and study conditions.
Related material for LNP research.
View product →Related material for LNP research.
View product →Related material for LNP research.
View product →Related material for LNP research.
View product →Related material for LNP research.
View product →Related material for LNP research.
View product →Related material for LNP research.
View product →Related material for LNP research.
View product →Related material for LNP research.
View product →Related material for LNP research.
View product →| Chemical Name | LQ089 |
| CAS No. | Not reported |
| Synonyms | LQ-089; LQ 089 |
| Formula | C43H83NO5 |
| M.Wt | 694.139 |
| SMILES | CCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC1CCCCC1 |
| Purity | Please confirm with sales |
| Storage | Please confirm with sales |
| Publication | Wang et al., Nature Communications 15, 10804 (2024). DOI:10.1038/s41467-024-55072-6; CN118506877A |
The article and its Supplementary Information report separate IV screening, IV/IM organ studies, storage and acute-toxicity experiments. Their doses, timepoints and cohorts are kept separate.
Research use only. DC Chemicals supplies the lipid only; literature LNP performance depends on the complete formulation and experimental conditions and is not guaranteed.
Wang et al.2024; main17pages and SI77pages · Wang et al., Nature Communications 15, 10804 (2024)
LQ089 : DSPC : Cholesterol : DMG-PEG2000 = 50 : 10 : 38.5 : 1.5
Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
| Component | MW (g/mol) | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|
| LQ089 · DCL0031 | 694.139 | 50 | 0.347069 |
| DSPC · DC57005 | 790.145195960999 | 10 | 0.079015 |
| Cholesterol · DCD-041 | 386.65 | 38.5 | 0.148860 |
| DMG-PEG2000 · DC40169 | 2507 | 1.5 | 0.037605 |
Masses are calculated conversions. Editing inputs creates a research scenario; the reported table remains unchanged.
| Component | MW (g/mol) | Molar ratio | mg | Mass % |
|---|---|---|---|---|
| LQ089 | — | — | ||
| DSPC | — | — | ||
| Cholesterol | — | — | ||
| DMG-PEG2000 | — | — |
Masses are calculated conversions. Editing inputs creates a research scenario; the reported table remains unchanged.
Main Methods,p14; SI Table 9, PDF p. 10 · Wang et al., Nature Communications 15, 10804 (2024)
SI Table9 reports mean±SD,n=3 for particle characterization. No numerical SD is given for EE or pKa.
| Particle size | 60.900 ± 0.095 nm |
|---|---|
| PDI | 0.111 ± 0.004 |
| Encapsulation efficiency | 95.650% |
| N/P | 6:1; Nitrogen/phosphate counting definition not stated |
| Lipid stock | Ethanol;individual concentrations not reported |
| RNA aqueous phase | Firefly luciferase mRNA; Cap1; T7 in vitro transcription. Acidic citrate;strength,pH and RNA concentration not reported |
| Mixed ethanolic phase | 12.5 mM total lipid; Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated. |
| PNI | 12 mL/min; aqueous:ethanol3:1 (v/v) |
| Dialysis / PBS | 12–24 h; 0.01 M PBS; Amicon-Ultra10 kDa; 0.22 µm |
Individual lipid-stock concentrations,RNA input concentration,citrate-buffer strength/pH,injection volume and final administration concentration are not supplied.
Main PDF pp. 14–15; SI Table 9, PDF p. 10 · Wang et al., Nature Communications 15, 10804 (2024)
Main Methods, PDF p. 15; SI Table 9, PDF p. 10 · Wang et al., Nature Communications 15, 10804 (2024)
| pH | 2.0–12.0; 2 M NaOH / 2 M HCl |
|---|---|
| Basal buffer | 10 mM sodium phosphate +10 mM sodium borate +10 mM sodium citrate +150 mM NaCl |
| Per well | 94 µL buffer +4 µL LNP (0.05 mg/mL mRNA, PBS) +2 µL TNS (300 µM,10% DMSO) |
| Incubation | 7 min; room temperature; protected from light |
| Readout / analysis | Ex 325 nm / Em 435 nm; fluorescence–pH; LogEC50 |
| Calculated from reported aliquots | 100 µL total; TNS 6 µM; mRNA 2 µg/mL; DMSO 0.2% |
Main Methods, PDF p. 15; SI Table 9, PDF p. 10 · Wang et al., Nature Communications 15, 10804 (2024)
Rabbit erythrocyte hemolysis is reported. The article/SI does not report a separate LQ089 cellular mRNA-transfection or cell-viability experiment.
Main PDF p. 9; SI Fig.19,p30 · Wang et al., Supplementary Information
Rabbit-RBC hemolysis was reported negative. Mix100µL2%RBC suspension with100µL LNP at50µg/mL mRNA;37°C for3h;supernatant absorbance540nm;n=3,mean±SD. Calculated final conditions:1%RBC and25µg/mL mRNA. Saline and ultrapure water are controls.
SI Fig.19,p30 · Wang et al., Supplementary Information
These results concern complete research LNPs in mice. Injection volumes and final dosing concentrations are not given. A nonsignificant comparison does not establish equivalence or clinical safety.
MainFigs4,6–10; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)
IV screening: LQ089 exceeded MC3 in the 4–48h expression AUC; its comparison with SM-102 was nonsignificant. LQ089n=3,MC3n=6,SM-102n=5; mean±SD,one-wayANOVA. A numerical fold change is not specified in the text.
| Model | Female BALB/c,6–8weeks |
|---|---|
| Route | IV |
| Dose / basis | 5 µg mRNA / mouse |
| Timepoints | 4, 24, 48 h; AUC4–48 h |
Resultspp5–6,Fig.4d–e; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)
IV organ study: the liver was the principal reporter-expression organ at4h. LQ089 showed no significant difference from SM-102. Each group comprised3female+3male BALB/c mice; mean±SD,one-wayANOVA.
| Model | BALB/c,3female+3male/group |
|---|---|
| Route | IV |
| Dose / basis | 5 µg mRNA / mouse |
| Timepoints | 4 h |
Main PDF pp. 7–8,Fig.6a–c; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)
IM organ study: expression was detected at the injection site and in the liver at4h. This formulation is not described as local-only delivery. Each group comprised3female+3male BALB/c mice; mean±SD,one-wayANOVA.
| Model | BALB/c,3female+3male/group |
|---|---|
| Route | IM |
| Dose / basis | 5 µg mRNA / mouse |
| Timepoints | 4 h |
Main PDF pp. 8–9,Fig.7; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)
Cy5-mRNA distribution: most of the small recovered organ-associated signal was in the liver at4h after IV dosing. This is labeled-RNA distribution,not expressed-protein bioluminescence. SI Fig.13b:n=3,mean±SD.
| Model | BALB/c;n=3;cohort sex not separately stated |
|---|---|
| Route | IV |
| Dose / basis | 5 µg Cy5-mRNA / mouse |
| Timepoints | 4 h |
Main PDF pp. 7–8; Methods, PDF p. 15; SI Fig.13b,p24 · Wang et al., Supplementary Information
LQ089 LNP particle properties remained acceptable during30days at4°C,−20°C and−80°C,while in vivo expression decreased. Freeze/thaw modestly affected expression. Interim sampling is Day14 in text but Day15 on Fig.8axes; cycle count is not stated. These results do not set neat-lipid shelf life.
| Model | Female BALB/c,6–8weeks |
|---|---|
| Route | IV |
| Dose / basis | 5 µg mRNA / mouse |
| Timepoints | 4°C / −20°C / −80°C; Day0,14/15,30 |
Main PDF p. 8; Fig.8a–h,p10 · Wang et al., Nature Communications 15, 10804 (2024)
Acute test:20 or100µg mRNA/mouse IV(source:1 or5mg/kg),4female+4male mice per dose,saline placebo,14-day follow-up. A slight ALT rise was reported for LQ089 at100µg; no obvious H&E abnormality was reported. This does not establish clinical safety.
| Model | BALB/c,4female+4male/dose |
|---|---|
| Route | IV |
| Dose / basis | 20 / 100 µg mRNA / mouse (1 / 5 mg/kg) |
| Timepoints | Day1,2,3,4,7,9,11,13,14 |
Main PDF pp. 8–9; Fig.9,p11; Fig.10,p13; Methods, PDF p. 15; SI Figs.16–18,pp27–29 · Wang et al., Nature Communications 15, 10804 (2024)
Original mainFigs4,6–10 and SI Figs13,18,19 · Wang et al., Nature Communications 15, 10804 (2024)

Fig4, PDFp6 · Wang et al., Nature Communications 15, 10804 (2024)

Fig6, PDFp8 · Wang et al., Nature Communications 15, 10804 (2024)

Fig7, PDFp9 · Wang et al., Nature Communications 15, 10804 (2024)

Fig8, PDFp10 · Wang et al., Nature Communications 15, 10804 (2024)

Fig9, PDFp11 · Wang et al., Nature Communications 15, 10804 (2024)

Fig10, PDFp13 · Wang et al., Nature Communications 15, 10804 (2024)

FigS13, PDFp24 · Wang et al., Supplementary Information

FigS18, PDFp29 · Wang et al., Supplementary Information

FigS19, PDFp30 · Wang et al., Supplementary Information
Rabbit erythrocyte hemolysis is reported. The article/SI does not report a separate LQ089 cellular mRNA-transfection or cell-viability experiment.
SI Fig.19,p30 · Wang et al., Supplementary Information
| Model | Rabbit erythrocytes |
|---|---|
| Route | In vitro / ex vivo |
| Dose / basis | 100 µL LNP (50 µg/mL mRNA) + 100 µL RBC (2%) |
| Timepoints | 37°C; 3 h; A540nm |
| Replicates / statistics | n=3; mean±SD; saline / ultrapure water |
Ethanol;individual concentrations not reported
Ethanol
Acidic citrate;strength,pH and RNA concentration not reported
Acidic citrate;strength,pH and RNA concentration not reported
Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
12.5 mM · Mixed ethanolic phase
Rabbit-RBC hemolysis was reported negative. Mix100µL2%RBC suspension with100µL LNP at50µg/mL mRNA;37°C for3h;supernatant absorbance540nm;n=3,mean±SD. Calculated final conditions:1%RBC and25µg/mL mRNA. Saline and ultrapure water are controls.
50 µg/mL mRNA · 100 µL LNP
Holding/storage for this specific experiment not separately stated
Main PDF p. 9; SI Fig.19,p30 · Wang et al., Supplementary Information
Individual lipid-stock concentrations,RNA input concentration,citrate-buffer strength/pH,injection volume and final administration concentration are not supplied.
Main PDF pp. 14–15; Figs4,6–10 · Wang et al., Nature Communications 15, 10804 (2024)
| Animal housing / allocation | 20–26°C,50–60%RH,10h light/14h dark,6mice/cage;food/water ad libitum. Random group assignment; no data excluded. Fudan University IACUC approval. Female screening mice:Vital River. |
|---|
Main Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)
| Model | Female BALB/c,6–8weeks |
|---|---|
| Route | IV |
| Dose / basis | 5 µg mRNA / mouse |
| Timepoints | 4, 24, 48 h; AUC4–48 h |
| Replicates / statistics | LQ089n=3; MC3n=6; SM-102n=5; mean±SD; one-wayANOVA |
Ethanol;individual concentrations not reported
Ethanol
Acidic citrate;strength,pH and RNA concentration not reported
Acidic citrate;strength,pH and RNA concentration not reported
Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
12.5 mM · Mixed ethanolic phase
5 µg mRNA / mouse; Injection volume and final concentration not reported
5 µg mRNA / mouse
Holding/storage for this specific experiment not separately stated
Resultspp5–6,Fig.4d–e; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)
| Model | BALB/c,3female+3male/group |
|---|---|
| Route | IV |
| Dose / basis | 5 µg mRNA / mouse |
| Timepoints | 4 h |
| Replicates / statistics | n=6 (3F+3M); mean±SD; one-wayANOVA |
Ethanol;individual concentrations not reported
Ethanol
Acidic citrate;strength,pH and RNA concentration not reported
Acidic citrate;strength,pH and RNA concentration not reported
Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
12.5 mM · Mixed ethanolic phase
5 µg mRNA / mouse; Injection volume and final concentration not reported
5 µg mRNA / mouse
Holding/storage for this specific experiment not separately stated
Main PDF pp. 7–8,Fig.6a–c; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)
| Model | BALB/c,3female+3male/group |
|---|---|
| Route | IM |
| Dose / basis | 5 µg mRNA / mouse |
| Timepoints | 4 h |
| Replicates / statistics | n=6 (3F+3M); mean±SD; one-wayANOVA |
Ethanol;individual concentrations not reported
Ethanol
Acidic citrate;strength,pH and RNA concentration not reported
Acidic citrate;strength,pH and RNA concentration not reported
Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
12.5 mM · Mixed ethanolic phase
5 µg mRNA / mouse; Injection volume and final concentration not reported
5 µg mRNA / mouse
Holding/storage for this specific experiment not separately stated
Main PDF pp. 8–9,Fig.7; Methods, PDF p. 15 · Wang et al., Nature Communications 15, 10804 (2024)
| Model | BALB/c;n=3;cohort sex not separately stated |
|---|---|
| Route | IV |
| Dose / basis | 5 µg Cy5-mRNA / mouse |
| Timepoints | 4 h |
| Replicates / statistics | n=3; mean±SD |
Ethanol;individual concentrations not reported
Ethanol
Acidic citrate;strength,pH and RNA concentration not reported
Acidic citrate;strength,pH and RNA concentration not reported
Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
12.5 mM · Mixed ethanolic phase
5 µg Cy5-mRNA / mouse; Injection volume and final concentration not reported
5 µg Cy5-mRNA / mouse
Holding/storage for this specific experiment not separately stated
Main PDF pp. 7–8; Methods, PDF p. 15; SI Fig.13b,p24 · Wang et al., Nature Communications 15, 10804 (2024)
| Model | Female BALB/c,6–8weeks |
|---|---|
| Route | IV |
| Dose / basis | 5 µg mRNA / mouse |
| Timepoints | 4°C / −20°C / −80°C; Day0,14/15,30 |
| Replicates / statistics | n=3; mean±SD; no significance test |
Ethanol;individual concentrations not reported
Ethanol
Acidic citrate;strength,pH and RNA concentration not reported
Acidic citrate;strength,pH and RNA concentration not reported
Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
12.5 mM · Mixed ethanolic phase
5 µg mRNA / mouse; Injection volume and final concentration not reported
5 µg mRNA / mouse
LQ089 LNP particle properties remained acceptable during30days at4°C,−20°C and−80°C,while in vivo expression decreased. Freeze/thaw modestly affected expression. Interim sampling is Day14 in text but Day15 on Fig.8axes; cycle count is not stated. These results do not set neat-lipid shelf life.
Formulated LQ089 LNPs at4°C,−20°C,−80°C; thaw at room temperature. Interim Day14(text)/Day15(axes); terminal Day30. Cycle count and holding times not given.
Main PDF p. 8; Fig.8a–h,p10 · Wang et al., Nature Communications 15, 10804 (2024)
| Model | BALB/c,4female+4male/dose |
|---|---|
| Route | IV |
| Dose / basis | 20 / 100 µg mRNA / mouse (1 / 5 mg/kg) |
| Timepoints | Day1,2,3,4,7,9,11,13,14 |
| Replicates / statistics | n=8 (4F+4M); mean±SD; one-wayANOVA |
Ethanol;individual concentrations not reported
Ethanol
Acidic citrate;strength,pH and RNA concentration not reported
Acidic citrate;strength,pH and RNA concentration not reported
Total lipid concentration in the mixed ethanolic phase: 12.5 mM. The concentration after aqueous mixing is not specified. N/P is 6:1; the nitrogen/phosphate counting convention is not stated.
12.5 mM · Mixed ethanolic phase
20 / 100 µg mRNA / mouse (1 / 5 mg/kg); Injection volume and final concentration not reported
20 / 100 µg mRNA / mouse (1 / 5 mg/kg)
Holding/storage for this specific experiment not separately stated
Main PDF pp. 8–9; Fig.9,p11; Fig.10,p13; Methods, PDF p. 15; SI Figs.16–18,pp27–29 · Wang et al., Nature Communications 15, 10804 (2024)
Wang W, Chen K, Jiang T, et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. Nature Communications15,10804(2024). · Wang et al., Nature Communications 15, 10804 (2024)
SI§2.4,pp45–51; Table 9, PDF p. 10; Figs13,18,19 · Wang et al., Supplementary Information
Molecular weight is prefilled from the product record. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 14.4063 mL | 2.8813 mL | 1.4406 mL |
| 25 mg | 36.0158 mL | 7.2032 mL | 3.6016 mL |
| 50 mg | 72.0317 mL | 14.4063 mL | 7.2032 mL |
| 100 mg | 144.0634 mL | 28.8127 mL | 14.4063 mL |
| 250 mg | 360.1584 mL | 72.0317 mL | 36.0158 mL |
Contact our team with the catalog number and requested quantity.
